Jukka Huttunen1, Mitja I Kurki2, Mikael von Und Zu Fraunberg2, Timo Koivisto2, Antti Ronkainen2, Jaakko Rinne2, Juha E Jääskeläinen2, Reetta Kälviäinen2, Arto Immonen2. 1. From Neurosurgery (J.H., M.I.K., M.v.u.z.F., T.K., J.E.J., A.I.) and Neurology (R.K.), NeuroCenter, Kuopio University Hospital, and Faculty of Health Sciences, School of Medicine, Institute of Clinical Medicine, University of Eastern Finland, Kuopio; Neurosurgery (A.R.), Tampere University Hospital; and Neurosurgery (J.R.), Turku University Hospital, Finland. jukka.huttunen@kuh.fi. 2. From Neurosurgery (J.H., M.I.K., M.v.u.z.F., T.K., J.E.J., A.I.) and Neurology (R.K.), NeuroCenter, Kuopio University Hospital, and Faculty of Health Sciences, School of Medicine, Institute of Clinical Medicine, University of Eastern Finland, Kuopio; Neurosurgery (A.R.), Tampere University Hospital; and Neurosurgery (J.R.), Turku University Hospital, Finland.
Abstract
OBJECTIVE: The aim was to elucidate the incidence and risk factors of epilepsy after subarachnoid hemorrhage (SAH) from saccular intracranial aneurysm (sIA) in a population-based cohort. METHODS: The Kuopio sIA Database (www.uef.fi/ns) includes all unruptured and ruptured sIA cases admitted to the Kuopio University Hospital from its defined catchment population in Eastern Finland. The use of prescribed medicines, including reimbursable antiepileptic drugs, has been entered from the Finnish national registries. The cumulative incidence and independent risk factors of epilepsy and death were analyzed in 876 patients with sIA-SAH admitted from 1995 to 2007. The competing risks analysis was used to correctly estimate the probability of epilepsy, because epilepsy and death after sIA-SAH may share risk factors. RESULTS: The follow-up ended at death (n = 200) or December 31, 2008; median follow-up time was 76 months. Epilepsy was diagnosed in 113 patients in a median of 8 months after sIA-SAH. Cumulative incidence of epilepsy after sIA-SAH was 8% at 1 year and 12% at 5 years. Thirty-three percent of patients with intracerebral hemorrhage (ICH) >15 cm(3) developed epilepsy. In the 876 patients with sIA-SAH, the independent risk factors for epilepsy were ICH >15 cm(3), Hunt and Hess grade III-V, and acute seizures. CONCLUSIONS: Cumulative incidence of epilepsy is 12% at 5 years. Epilepsy and 12-month mortality after sIA-SAH share poor Hunt and Hess grading as an independent risk factor. Epilepsy in the 2-week survivors of sIA-SAH is predicted by signs of primary injury in the brain tissue, most notably ICH.
OBJECTIVE: The aim was to elucidate the incidence and risk factors of epilepsy after subarachnoid hemorrhage (SAH) from saccular intracranial aneurysm (sIA) in a population-based cohort. METHODS: The Kuopio sIA Database (www.uef.fi/ns) includes all unruptured and ruptured sIA cases admitted to the Kuopio University Hospital from its defined catchment population in Eastern Finland. The use of prescribed medicines, including reimbursable antiepileptic drugs, has been entered from the Finnish national registries. The cumulative incidence and independent risk factors of epilepsy and death were analyzed in 876 patients with sIA-SAH admitted from 1995 to 2007. The competing risks analysis was used to correctly estimate the probability of epilepsy, because epilepsy and death after sIA-SAH may share risk factors. RESULTS: The follow-up ended at death (n = 200) or December 31, 2008; median follow-up time was 76 months. Epilepsy was diagnosed in 113 patients in a median of 8 months after sIA-SAH. Cumulative incidence of epilepsy after sIA-SAH was 8% at 1 year and 12% at 5 years. Thirty-three percent of patients with intracerebral hemorrhage (ICH) >15 cm(3) developed epilepsy. In the 876 patients with sIA-SAH, the independent risk factors for epilepsy were ICH >15 cm(3), Hunt and Hess grade III-V, and acute seizures. CONCLUSIONS: Cumulative incidence of epilepsy is 12% at 5 years. Epilepsy and 12-month mortality after sIA-SAH share poor Hunt and Hess grading as an independent risk factor. Epilepsy in the 2-week survivors of sIA-SAH is predicted by signs of primary injury in the brain tissue, most notably ICH.
Authors: Theresa Human; Michael N Diringer; Michelle Allen; Gregory J Zipfel; Michael Chicoine; Ralph Dacey; Rajat Dhar Journal: Neurocrit Care Date: 2018-04 Impact factor: 3.210
Authors: S Y Bögli; D Utebay; N Smits; L P Westphal; L Hirsbrunner; S Unseld; E Keller; G Brandi Journal: Acta Neurochir (Wien) Date: 2022-08-19 Impact factor: 2.816
Authors: Baxter B Allen; Peter B Forgacs; Malik A Fakhar; Xian Wu; Linda M Gerber; Srikanth Boddu; Santosh B Murthy; Philip E Stieg; Halinder S Mangat Journal: Neurocrit Care Date: 2018-08 Impact factor: 3.210
Authors: Alexander E Merkler; Gino Gialdini; Michael P Lerario; Neal S Parikh; Nicholas A Morris; Benjamin Kummer; Lauren Dunn; Michael E Reznik; Santosh B Murthy; Babak B Navi; Zachary M Grinspan; Costantino Iadecola; Hooman Kamel Journal: Stroke Date: 2018-04-25 Impact factor: 7.914
Authors: Jukka Huttunen; Antti Lindgren; Mitja I Kurki; Terhi Huttunen; Juhana Frösen; Timo Koivisto; Mikael von Und Zu Fraunberg; Arto Immonen; Juha E Jääskeläinen; Reetta Kälviäinen Journal: Neurology Date: 2017-06-14 Impact factor: 9.910